Research Article

Clinical Significance of Epigenetic Inactivation of hMLH1 and BRCA1 in Tunisian Patients with Invasive Breast Carcinoma

Sondes Karray-Chouayekh,1 Fatma Trifa,1 Abdelmajid Khabir,2 Nouredine Boujelbane,2 Tahia Sellami-Boudawara,2 Jamel Daoud,2 Mounir Frikha,2 Ali Gargouri,1 and Raja Mokdad-Gargouri1

1 Unité de Génétique du cancer et Production de protéines thérapeutiques, Centre de Biotechnologie de Sfax, route Sidi Mansour, BP “1177”, 3018 Sfax, Tunisia
2 Centre Hospitalier Universitaire Habib Bourguiba, 3000 Sfax, Tunisia

Correspondence should be addressed to Raja Mokdad-Gargouri, raja.gargouri@cbs.rnrt.tn

Received 14 February 2009; Accepted 19 May 2009

Recommended by Xin-yuan Guan

Aberrant hypermethylation of gene promoter regions is one of the mechanisms for inactivation of tumour suppressor genes in many human cancers including breast carcinoma. In the current study, we aimed to assess by MSP, the methylation pattern of two cancer-related genes involved in DNA repair: hMLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) and BRCA1 (breast cancer 1, early onset) in 78 primary breast cancers from Tunisian patients. The methylation frequencies were 24.36% for hMLH1 and 46% for BRCA1. BRCA1 methylation correlated with age at diagnosis ($P = .015$) and 5-years disease free survival ($P = .016$) while hMLH1 methylation was more frequent in larger tumors ($P = .002$) and in presence of distant metastasis ($P = .004$). Furthermore, methylation of hMLH1 significantly correlated with high level of P53 expression ($P = .006$) and with overall survival ($P = .015$) suggesting that silencing of hMLH1 through aberrant promoter methylation could be used as a poor prognosis indicator in breast cancer.

1. Introduction

Breast cancer is the first cause of cancer mortality among women worldwide and the overall lifetime risk for developing invasive breast cancer is estimated to 10% [1]. In Tunisia, breast cancer is the second most frequent cancer among females and in the south area the incidence is of 30/100000 [2]. Tunisian breast cancer is characterized by a particular aggressive profile compared with Western countries as the incidence is more prevalent in young (<35 years) than older patients [3]. Breast cancer results of abnormal genetic as well as epigenetic changes [4]. Promoter-CpG islands hypermethylation, associated with global hypomethylation, are common molecular defects in cancer cells [5].

CpG islands, frequently located at the 5’-end regulatory regions of genes, are subject to epigenetic modifications including DNA methylation and histone modification that are known to play an important role in regulating gene expression [5]. In normal cells, the majority of promoter CpG islands are protected from this epigenetic event and thus they are unmethylated. Conversely, in cancer cells, several promoter CpG islands are hypermethylated and form a closed repressive chromatin configuration that affects the transcription initiation of the corresponding genes [6–8].

Recent studies suggested that methylation profiles of cancers depend on tumor type and ethnicity [13, 14]. In this context, the methylation status of breast cancer patients from Western population is well documented whereas that of Tunisian breast cancer is still not well studied except a recent work on the relationship between SV40 status and promoter
Table 1: Summary of primer sequences, annealing temperature, product size and number of cycle used in MSP assay. M: methylated DNA, U: unmethylated DNA, F: forward, R: Reverse.

| Gene     | Sequence (5'-3') | Tm (°C) | Size (bp) | PCR cycles |
|----------|------------------|---------|-----------|------------|
| hMLH1 (U) | F TTTTGAATGATAGTTTTATTAGGGTTGT | 60 | 114 | 30 |
| R ACCACCATCATAACTACCACA | | | | |
| hMLH1 (M) | F ACGTAGACGTTTATAGGGTCGC | 58 | 110 | 30 |
| R CCTATCGTAATCCCGCGG | | | | |
| BRCA1I (U) | F GGTTAATTAGGTGGAGATG | 60 | 75 | 30 |
| R TCAACAAACTCACACACACAATCA | | | | |
| BRCA1 (M) | F GGTTAATTAGGTGGAGAGCG | 60 | 86 | 30 |
| R TCAACGAACTCACGCGCGCGGAATCG | | | | |

proteinase K at 55°C for 4 hours. DNA was extracted with a mixture of phenol-chloroform-isoamyl alcohol (25 : 24 : 1) and precipitated with ethanol at −20°C. The quantity of DNA was checked by spectrophotometer and stored at −20°C for further use.

2.3. Methylation-Specific-PCR (MSP). DNA samples (1 to 2 μg) were modified with sodium bisulfite that converts the unmethylated cytosines but not the methylated ones to uracil using the Methyl Detector Kit as recommended by Active Motif (Belgium). The bisulfite-treated DNA was amplified using specific primers for methylated and unmethylated alleles as described by Herman et al. [28]. Sequences of the primers, annealing temperature, and product size are listed in Table 1.

PCR was carried out in a total volume of 25 μL containing 2 μM of each primer pair, 200 μM dNTP, 1.5 mM MgCl2, 1X PCR buffer, and 1 U of Taq DNA polymerase (Fermentas). Each PCR reaction underwent initial denaturation at 95°C for 10 minutes, and 35 cycles of the following profile: 30 seconds at 94°C, 30 seconds at optimal T° (Table 1), and 30 seconds at 72°C followed by a final 10 minutes extension at 72°C. Fully methylated DNA (Active Motif, Belgium) and lymphocytes DNA from healthy individual were used as positive controls for the methylated and unmethylated reactions, respectively. Blank control without DNA was included in each PCR assay. After amplification, products were electrophoresed using 2% agarose gels, stained with ethidium bromide and visualized under UV illumination.

2.4. Immunohistochemistry: Immunostaining of Estrogen (ER) and Progesteron (PR) receptors was performed for all specimens, while HER/neu and p53 protein expression was investigated in 64 and 39 specimens, respectively. Four micrometers sections attached on silanized slides were dewaxed in xylene, rehydrated in graded ethanol, and covered with 10 μM citrate buffer (pH 6). Slides were incubated for 30 minutes with primary monoclonal antibodies against: ER (Dako, clone 1D5, 1 : 25), PR (Dako, clone PgR636, 1 : 50), HER/neu (Dako, clone 124, 1 : 100), and p53 (clone DO-7, Dako Cytomation 1 : 50) followed by incubation with biotin-labelled secondary antibodies. The streptavidin-peroxidase complex was visualized using diaminobenzidine.
as a chromogenic substrate. All slides were evaluated without knowledge of the clinical outcome. Sections were considered to be positive if more than 5% of tumor cells were stained. For each run of staining, positive control slides were prepared from breast carcinoma known to be positive for the proteins under study. The HER2/neu and p53 immunostaining were scored from 0 to 3 according to the criteria set by Dako. The staining was scored as negative (0) when no membrane staining was observed for HER2/neu, and no nuclear staining for p53, or when staining was observed in less than 10% of the tumor cells, weak positive (1+) if weak focal staining was seen in more than 10% of the tumor cells, intermediate (2+), if weak to moderate, complete staining was seen in more than 10% of the tumor cells and strongly positive (3+) if intense and complete staining in more than 10% of the tumor cells. In the final analysis, scores 0, 1, and 2 were considered as negative, only score 3 was retained as positive in HER2/neu and no nuclear staining for p53, or when staining was observed in less than 10% of the tumor cells.

2.5. Data Analysis and Statistics. The association between aberrant hypermethylation and clinicopathological parameters was checked by the χ² test. All variables (age, stage, histological grade, lymph node involvement, distant metastasis, hormone receptor status, and CpG island hypermethylation) were also subjected to multivariate analysis using Logistic regression. Survival curves were constructed according to the method of Kaplan Meier. For differences between curves, the P value was calculated using the log rank test. All the statistical analysis was performed using the software SPSS for Windows version 13.0. P < .05 was considered as statistically significant.

3. Results and Discussion

3.1. Methylation Profiles of BRCA1 and hMLH1 in Tumor Tissues. Aberrant methylation of the promoter region is considered as one of the major mechanisms for silencing of cancer-related genes, resulting in downregulation of gene expression. It has been demonstrated that CpG islands hypermethylation is implicated in the loss of expression of critical tumor suppressor and growth regulatory genes leading to cancer development and progression [5–8]. Analysis of promoter methylation of BRCA1 and hMLH1 was carried out in 78 and 74 invasive primary breast tissues, respectively. Figure 1 shows representative examples of MSP results. The frequency of promoter hypermethylation was 44.8% (35 out of 78) for BRCA1 and 24.3% (17 out of 74) for hMLH1. Among the 78 malignant tissues, more than a half exhibited at least one methylated gene (62%). In other hand, for some samples, we observed both the methylated and unmethylated alleles, this can be probably explained by the presence of infiltrating lymphocytes and/or nonmalignant epithelial cells in the primary tumors.

When we reviewed the literature, the methylation frequency ranged from 8 to 43.5% for hMLH1 and from 11 to 60% for BRCA1 [20, 29–32]. In our series, the frequencies of BRCA1 and hMLH1 methylation were in the middle of the range of previous studies. These differences may be explained by several factors: (i) unmethylated DNA from the normal cells infiltrating the tumor might attenuate the methylation levels and (ii) number of CpG within the region of interest. To avoid misinterpretation of our results, we included in each assay, both methylated and unmethylated DNA as controls.

On the other hand, several investigations have attempted to identify the racial/ethnic differences in promoter hypermethylation. Bae et al. evaluated promoter methylation status in American and Korean breast cancers patients and they found no significant interethnic differences [13]. More recently, it was reported that there are many similarities of promoter hypermethylation profiles between Korean and Caucasian women, but also dissimilarities that characterize tumors of one ethnicity from the other [14].

3.2. Relationship between Methylation Status and Clinicopathological Characteristics. The relationship between promoter hypermethylation of hMLH1 and BRCA1 genes and clinicopathological parameters was summarized in Table 2. Statistical analysis showed that BRCA1 hypermethylation was associated with age at diagnosis (P = .015, Table 2) since 72% of patients ≤45 years displayed the methylated pattern. This observation suggests that loss of BRCA1 expression through aberrant promoter methylation occurred more frequently in young women with breast carcinoma.
Table 2: Association between gene promoter methylation and clinicopathological features ER and p53 expression in breast cancer.

| Clinical features | BRCA1 | hMLH1 |
|-------------------|-------|-------|
|                   | M (%) | U (%) | M (%) | U (%) |
| N                 | 78    |       | 78    |       |
| Age               |       |       |       |       |
| ≤45               | 30    | 19 (63.3) | 17 (21.4) | 11 (36.7) | 6 (21.4) |
| >45               | 48    | 16 (33.3) | 11 (23.9) | 32 (66.7) | 22 (78.6) |
| Tumor size        |       |       |       |       |
| T ≤ 30 mm         | 38    | 18 (47.4) | 3 (8.1) | 20 (52.6) | 34 (91.9) |
| T > 30 mm         | 40    | 17 (42.5) | 14 (37.8) | 23 (57.5) | 23 (62.2) |
| Metastasis        |       |       |       |       |
| No                | 37    | 18 (48.6) | 1 (2.8) | 19 (51.4) | 35 (97.2) |
| Yes               | 14    | 8 (37.1) | 4 (30.8) | 6 (42.9) | 9 (69.2) |
| DFS               |       |       |       |       |
| <5 years          | 22    | 7 (31.8) | 3 (14.3) | 15 (68.2) | 18 (87.5) |
| >5 years          | 12    | 9 (75) | 1 (8.3) | 3 (25) | 11 (91.7) |
| Response to radiotherapy |       |       |       |       |
| Radiosensitive    | 37    | 18 (48.6) | 1 (2.8) | 19 (51.4) | 35 (97.2) |
| Radioresistant    | 14    | 8 (57.1) | 4 (30.8) | 6 (42.9) | 9 (69.2) |
| ER                |       |       |       |       |
| Positive          | 19    | 9 (47.4) | 7 (36.8) | 10 (52.6) | 12 (63.2) |
| Moderate          | 28    | 11 (39.3) | 2 (7.7) | 17 (60.7) | 24 (92.3) |
| Negative          | 31    | 15 (48.4) | 8 (27.6) | 16 (51.6) | 21 (72.4) |
| P53               |       |       |       |       |
| Positive          | 16    | 9 (56.3) | 5 (68.8) | 7 (43.8) | 11 (31.3) |
| Negative          | 23    | 10 (43.5) | 0 (0) | 13 (56.5) | 21 (100) |

DFS: Disease Free Survival, ER: Estrogen Receptor.

(a) Data for DFS, response to radiotherapy, metastasis, and p53 status were not available for all specimens.

(b) Comparisons of DFS and P53 status were made by Fisher’s exact test and all other comparisons were by the 2 test.

which is known to have a particular more aggressive feature. Despite age, no other association was found with patients’ characteristics and BRCA1 methylation status. Nevertheless, by multivariate analysis, we found a significant association of BRCA1 promoter methylation with clinical stage, tumor size and 5-year survival ($P = .022, .037$ and .017, resp., Table 3).

The most consistent associations were seen between hMLH1 promoter hypermethylation and tumor size and distant metastasis ($P = .002$ and .004, resp., Table 2). This result leads us to suggest that hypermethylation of hMLH1 gene promoter seemed to confer advantage for tumors cells invasion, and it may be used as a marker of advanced breast cancer. In this context, it was reported that hypermethylation of hMLH1 was significantly associated with advanced stage and lymphatic metastasis [19, 29]. Our finding is consistent with those studies since a trend of association was found between methylated hMLH1 profile and clinical stage of breast cancer. In fact, 14.3% of hMLH1 methylated tumors are of stage T III, IV versus 4.8% of early stage although

Table 3: Multivariate analysis of BRCA1 methylation status and clinical features.

| Clinical features | BRCA1 Methylation |
|-------------------|-------------------|
|                   | P     | OR   | 95%CI |
| Age               | .11   | 0.17 | 0.02–1.5 |
| TNM               | .218  | 0.173 | 0.01–2.81 |
| Clinical stage    | .022  | 53.8 | 1.7–1640 |
| Metastasis        | .891  | 0.8  | 0.03–16.6 |
| Tumor size        | .037  | 0.05 | 0.004–0.84 |
| 5-y survival      | .017  | 20.7 | 1.7–251.5 |
3.3. Relationship between Methylation of Individual Genes and ER, PR, HER2/neu, and P53 Status. The ER, PR, and HER2/neu are important prognostic biomarkers and therapeutic targets in primary breast cancer. ER-negative tumors appear to be more malignant, resulting in a poorer prognosis than ER-positive tumors [33, 34]. Expression of HER2/neu, ER, and PR proteins are considered as predictive marker for response to hormone therapy in breast cancer. High to moderate level of ER expression was detected in 60.3% of tumors while 39.7% of cases were ER-

|                | N  | ER⁻/PR⁺ | No   | ER⁻/HER2⁻ | No | ER⁻/PR⁻/HER2⁻ | No |
|----------------|----|---------|------|------------|----|---------------|----|
| **P53**        |    |         |      |            |    |               |    |
| Positive       | 16 | 10 (62.5%) | 6 (37.5%) | 8 (50%) | 8 (50%) | 7 (43.8%) | 9 (56.3%) |
| Negative       | 23 | 3 (13%) | 20 (87%) | 3 (13%) | 20 (87%) | 2 (8.7%) | 21 (91.3%) |
| *P* (t-test)   |    | **.001** |           | **.011** |           | **.01**  |            |

In the current study, p53 expression was assessed by IHC in 39 specimens. Nuclear staining was seen in 41% (16 out of 39) of cases. Figure 2 shows an example of specimen with p53 positive (a) and negative (b) nuclear staining. Interestingly, we found that all tumors displaying unmethylated hMLH1 profile were negative for p53 (P = .004, Table 2). This observation suggests a positive association between methylated hMLH1 and functional p53. Furthermore, p53 expression was significantly connected to hormone receptor status. Indeed, high level of p53 expression was associated with double negative (ER⁻/PR⁻, P = .001 and ER⁻/HER2⁻, P = .011, Table 4) and triple negative (ER⁻/PR⁻/HER2⁻, P = .01, Table 4) tumors. Our data was consistent with previously reported results showing that triple negative breast cancers correlated with high p53 expression level [37]. It was well established that triple negative breast cancer has aggressive clinical features and reduced survival [38]. In the current work, we showed that triple negative breast cancer correlated with 5-year survival, (P = .002; OR = 0.083, 95% CI = 0.015–0.462) while no statistically significant association was found with overall survival and triple negative tumors in our series. Recently, Rhee et al., reported that most of the relapses in triple negative breast cancer occur within the first 3 years, in contrast to tumors expressing ER, PR, and HER2/neu [37].
Altogether, these findings reflect the aggressiveness of triple negative breast cancer as previously reported [38].

3.4. Relationship between Methylation of hMLH1 and Overall Survival. The survival rate was available for 34 patients and the follow-up time ranged from 3 to 119 months. The Kaplan-Meier method was used to correlate hMLH1 and BRCA1 methylation status with overall survival. As shown on Figure 3, patients with unmethylated hMLH1 gene promoter have a significant prolonged survival rate compared to those with methylated profile (P log rank = 0.015). To the best of our knowledge, this is the first report about the involvement of hMLH1 hypermethylation with patients’ outcome suggesting that it could be an important prognostic factor of breast cancer. However this finding should be confirmed on larger series. In the current study, BRCA1 methylation and survival association was of borderline significance (P log-rank = .065). Recently, it was reported in a large cohort of 851 patients that BRCA1 methylation was associated with breast cancer-specific mortality [39].

4. Conclusion

In summary, we examined BRCA1 and hMLH1 promoter methylation status and explored the relationship with clinicopathological factors and breast cancer survival. Promoter methylation of hMLH1 was more frequent in cancers with distant metastasis and in larger tumors (greater than 3 cm) whereas BRCA1 hypermethylation was higher in patients under 45 years. Furthermore, aberrant methylation of hMLH1 correlated with reduced overall survival while BRCA1 hypermethylation associated with 5-year survival. Our results indicate that BRCA1 and hMLH1 promoter methylation could be an important prognostic factor of breast cancer.

Acknowledgments

This work was supported by a Grant of the “Ministère de l’Enseignement Supérieur et de la Recherche Scientifique Tunisien”. The authors would like to thank all clinicians and pathologists at CHU Habib Bourguiba at Sfax-Tunisia, and Dr. Khemais Ben-Hadj for critical suggestions.

References

[1] E. J. Feuer, L.-M. Wun, C. C. Boring, W. D. Flanders, M. J. Timmel, and T. Tong, “The lifetime risk of developing breast cancer,” Journal of the National Cancer Institute, vol. 85, no. 11, pp. 892–897, 1993.
[2] N. Mourali, R. R. Muenz, F. Tabbane, S. Belhassen, J. Bahi, and P. H. Levine, “Epidemiologic features of rapidly progressing breast cancer in Tunisia,” Cancer, vol. 46, no. 12, pp. 2741–2746, 1980.
[3] D. M. Parkin, J. Ferlay, M. Hamdi-Cherif, et al., “Breast Cancer,” in Cancer in Africa: Epidemiology and Prevention, vol. 153, pp. 262–267, IARC Scientific, Lyon, France, 2003.
[4] J. Russo, X. Yang, Y. F. Hu, et al., “Biological and molecular basis of human breast cancer,” Frontiers in Bioscience, vol. 3, pp. D944–D960, 1998.
[5] P. A. Jones and S. B. Baylin, “The fundamental role of epigenetic events in cancer,” Nature Reviews Genetics, vol. 3, no. 6, pp. 415–428, 2002.
[6] M. Esteller, “CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future,” Oncogene, vol. 21, no. 35, pp. 3427–3440, 2002.
[7] M. Esteller, P. G. Corn, S. B. Baylin, and J. G. Herman, “A gene hypermethylation profile of human cancer,” Cancer Research, vol. 61, no. 8, pp. 3225–3229, 2001.
[8] S. B. Baylin and J. E. Ohm, “Epigenetic gene silencing in cancer: a mechanism for early oncogenic pathway addiction?” Nature Reviews Cancer, vol. 6, no. 2, pp. 107–116, 2006.
[9] B. B. Asch and M. H. Barcellos-Hoff, “Epigenetics and breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 6, no. 2, pp. 151–152, 2001.
[10] U. Lehmann, F. Langer, H. Feist, S. Hasemeier, and H. Kreipe, “Quantitative assessment of promoter hypermethylation during breast cancer development,” American Journal of Pathology, vol. 160, no. 2, pp. 605–612, 2002.
[11] M. Widschwendter and P. A. Jones, “DNA methylation and breast carcinogenesis,” Oncogene, vol. 21, no. 35, pp. 5462–5482, 2002.
[12] M. Szyf, P. Pakneshan, and S. A. Rabbani, “DNA methylation and breast cancer,” Biochemical Pharmacology, vol. 68, no. 6, pp. 1187–1197, 2004.
[13] Y. K. Bae, A. Brown, E. Garrett, et al., “Hypermethylation in histologically distinct classes of breast cancer,” Clinical Cancer Research, vol. 10, no. 18, part 1, pp. 5998–6005, 2004.
[14] J. S. Lee, P.-K. Lo, M. J. Fackler, et al., “A comparative study of Korean with Caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in Korean women,” Cancer Biology and Therapy, vol. 6, no. 7, pp. 1114–1120, 2007.
[15] M. Hachana, M. Trimeche, S. Ziadi, K. Amara, and S. Korbi, “Evidence for a role of the Simian Virus 40 in human breast carcinomas,” Breast Cancer Research and Treatment, vol. 113, no. 1, pp. 43–58, 2009.
[16] A. Catteau, W. H. Harris, C.-F. Xu, and E. Solomon, “Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics,” Oncogene, vol. 18, no. 11, pp. 1957–1965, 1999.
[17] T. Bianco, C. T. Georgia, C. A. W. David, E. C. John, and D. Alexander, “Tumor specific distribution of BRCA1 promoter region methylation supports a pathogenic role in breast and ovarian cancer,” Carcinogenesis, vol. 21, no. 2, pp. 147–151, 2000.
[18] D. T. Butcher and D. I. Rodenhiser, “Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours,” European Journal of Cancer, vol. 43, no. 1, pp. 210–219, 2007.
[19] H. Murata, N. H. Khattar, Y. Kang, L. Gu, and G.-M. Li, “Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability,” Oncogene, vol. 21, no. 37, pp. 5696–5703, 2002.
[20] H. Murata, N. H. Khattar, L. Gu, and G.-M. Li, “Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer,” Cancer Letters, vol. 223, no. 1, pp. 143–150, 2005.
[21] T. Jascur and C. R. Boland, “Structure and function of the components of the human DNA mismatch repair system,” International Journal of Cancer, vol. 119, no. 9, pp. 2030–2035, 2006.
[22] D. C. Thomas, A. Umar, and T. A. Kunkel, “Microsatellite instability and mismatch repair defects in cancer,” Mutation Research, vol. 350, no. 1, pp. 201–205, 1996.

[23] J. Jiricny, “The multifaceted mismatch-repair system,” Nature Reviews Molecular Cell Biology, vol. 7, no. 5, pp. 335–346, 2006.

[24] A. Catteau and J. R. Morris, “BRCA1 methylation: a significant role in tumour development?” Seminars in Cancer Biology, vol. 12, no. 5, pp. 359–371, 2002.

[25] C. W. Elston, I. O. Ellis, H. Goulging, and S. E. Pindre, “Role of pathology in the prognosis and management of breast cancer,” in Systemic Pathology, C. W. Elston and I. O. Ellis, Eds., vol. 13, pp. 385–433, 3rd edition, 1998.

[26] L. H. Sobin and Ch. Wittekind, Eds., International Union Against Cancer, TNM Classification of Malignant Tumours, Wiley-Liss, New York, NY, USA, 5th edition, 1997.

[27] J. Sambrook and D. W. Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2001.

[28] J. G. Herman, J. R. Graff, S. Myohanen, B. D. Nelkin, and S. B. Baylin, “Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 18, pp. 9821–9826, 1996.

[29] R. A. Naqvi, A. Hussain, S. S. V. Deo, et al., “Hypermethylation analysis of mismatch repair genes (hmlh1 and hmsh2) in locally advanced breast cancers in Indian women,” Human Pathology, vol. 39, no. 5, pp. 672–680, 2008.

[30] V. Birgisdottir, O. A. Stefansson, S. K. Bodvarsdottir, H. Hilmarssdottir, J. G. Jonasson, and J. E. Eyfjord, “Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer,” Breast Cancer Research, vol. 8, no. 4, pp. 1–10, 2006.

[31] M. Wei, T. A. Grushko, J. Dignam, et al., “BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy,” Cancer Research, vol. 65, no. 23, pp. 10692–10699, 2005.

[32] S. Li, M. Rong, and B. Iacopetta, “DNA hypermethylation in breast cancer and its association with clinicopathological features,” Cancer Letters, vol. 237, no. 2, pp. 272–280, 2006.

[33] M. J. Duffy, “Estrogen receptors: role in breast cancer,” Critical Reviews in Clinical Laboratory Sciences, vol. 43, no. 4, pp. 325–347, 2006.

[34] J. A. Rusiecki, T. R. Holford, S. H. Zahm, and T. Zheng, “Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status,” Cancer Detection and Prevention, vol. 29, no. 5, pp. 419–426, 2005.

[35] M. Campan, D. J. Weisenberger, and P. W. Laird, “DNA methylation profiles of female steroid hormone-driven human malignancies,” Current Topics in Microbiology and Immunology, vol. 310, pp. 141–178, 2006.

[36] M. Widschwendter, K. D. Siegmund, H. M. Müller, et al., “Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen,” Cancer Research, vol. 64, no. 11, pp. 3807–3813, 2004.

[37] J. Rhee, S.-W. Han, D.-Y. Oh, et al., “The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer,” BMC Cancer, vol. 8, no. 308, pp. 1–8, 2008.

[38] W. J. Irvin Jr. and L. A. Carey, “What is triple-negative breast cancer?” European Journal of Cancer, vol. 44, no. 18, pp. 2799–2805, 2008.